Immunodeficiency-associated lymphomas

Blood Reviews

Volumn 22, Issue 5, 2008, Pages 261-281

  Tran, Huy ^a   Nourse, Jamie ^b   Hall, Sara ^a   Green, Michael ^c   Griffiths, Lyn ^c   Gandhi, Maher K ^a,b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

Author keywords

Ataxia Telangiectasia; Combined variable immunodeficiency disorder; Diffuse large B cell lymphoma; Epstein barr virus; Hodgkin's lymphoma; Human herpes virus 8; Human immunodeficiency virus; Immunodeficiency; Infliximab; Lymphoma; Methotrexate; Post transplantation lymphoproliferative disorder; Primary central nervous system lymphoma; Primary effusion lymphoma; Rituximab

Indexed keywords

ACICLOVIR; ADALIMUMAB; ALEMTUZUMAB; ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ANTIRETROVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DOXORUBICIN; ETANERCEPT; GANCICLOVIR; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISOLONE; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; VINCRISTINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ATAXIA TELANGIECTASIA; BLOOD TOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMON VARIABLE IMMUNODEFICIENCY; CROHN DISEASE; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPER IGM SYNDROME; IMMUNOCOMPETENCE; LOW DRUG DOSE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEVERE COMBINED IMMUNODEFICIENCY; T CELL LYMPHOMA; WISKOTT ALDRICH SYNDROME; X CHROMOSOME LINKED DISORDER;

EPSTEIN-BARR VIRUS INFECTIONS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC DEFICIENCY SYNDROMES; LYMPHOMA; METHOTREXATE; TUMOR NECROSIS FACTOR-ALPHA; VIRUS LATENCY;

EID: 48149086402     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2008.03.009     Document Type: Article

References (175)

1. Burnet F.M. Immunological surveillance in neoplasia. Transplant Rev 7 (1971) 3-25
2. Khanna R., Bell S., Sherritt M., et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 96 (1999) 10391-10396
3. Dave S.S., Wright G., Tan B., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351 (2004) 2159-2169
4. Gandhi M.K., Lambley E., Duraiswamy J., et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 108 (2006) 2280-2289
5. Gandhi M.K., Moll G., Smith C., et al. Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 110 (2007) 1326-1329
6. Penn I., Hammond W., Brettschneider L., and Starzl T.E. Malignant lymphomas in transplantation patients. Transplant Proc 1 (1969) 106-112
7. Oertel S., and Reiss H. Immunosurveillance, immunodeficiency and lymphoproliferations (2002), Springer, Heidelberg
8. Geha R.S., Notarangelo L.D., Casanova J.L., et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 120 (2007) 776-794
9. Filipovich A.H., Stone J.V., Tomany S.C., et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 97 (2001) 1598-1603
10. Mosier D.E., Gulizia R.J., Baird S.M., and Wilson D.B. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 335 (1988) 256-259
11. Gronbaek K., Straten P.T., Ralfkiaer E., et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 92 (1998) 3018-3024
12. Kastan M.B., and Lim D.S. The many substrates and functions of ATM. Nat Rev Mol Cell Biol 1 (2000) 179-186
13. Barlow C., Hirotsune S., Paylor R., et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86 (1996) 159-171
14. Gulley M.L., Chen C.L., and Raab-Traub N. Epstein-Barr virus-related lymphomagenesis in a child with Wiskott-Aldrich syndrome. Hematol Oncol 11 (1993) 139-145
15. Laszewski M.J., Kemp J.D., Goeken J.A., Mitros F.A., Platz C.E., and Dick F.R. Clonal immunoglobulin gene rearrangement in nodular lymphoid hyperplasia of the gastrointestinal tract associated with common variable immunodeficiency. Am J Clin Pathol 94 (1990) 338-343
16. Dupre L., Andolfi G., Tangye S.G., et al. SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells. Blood 105 (2005) 4383-4389
17. Morra M., Howie D., Grande M.S., et al. X-linked lymphoproliferative disease: a progressive immunodeficiency. Annu Rev Immunol 19 (2001) 657-682
18. Harrington D.S., Weisenburger D.D., and Purtilo D.T. Malignant lymphoma in the X-linked lymphoproliferative syndrome. Cancer 59 (1987) 1419-1429
19. Milone M.C., Tsai D.E., Hodinka R.L., et al. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood 105 (2005) 994-996
20. Bagley J., Cortes M.L., Breakefield X.O., and Iacomini J. Bone marrow transplantation restores immune system function and prevents lymphoma in Atm-deficient mice. Blood 104 (2004) 572-578
21. Kawa K., Okamura T., Yasui M., Sato E., and Inoue M. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Crit Rev Oncol Hematol 44 (2002) 251-257
22. Williams L.L., Rooney C.M., Conley M.E., Brenner M.K., Krance R.A., and Heslop H.E. Correction of Duncan's syndrome by allogeneic bone marrow transplantation. Lancet 342 (1993) 587-588
23. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
24. Penn I. Cancers complicating organ transplantation. N Engl J Med 323 (1990) 1767-1769
25. Cesarman E., Chadburn A., Liu Y.F., Migliazza A., Dalla-Favera R., and Knowles D.M. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 92 (1998) 2294-2302
26. Young L.S., and Rickinson A.B. Epstein-Barr virus: 40 years on. Nat Rev Cancer 4 (2004) 757-768
27. Curtis R.E., Travis L.B., Rowlings P.A., et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94 (1999) 2208-2216
28. Boubenider S., Hiesse C., Goupy C., Kriaa F., Marchand S., and Charpentier B. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol 10 (1997) 136-145
29. Hezode C., Duvoux C., Germanidis G., et al. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation. Hepatology 30 (1999) 775-778
30. Finn L., Reyes J., Bueno J., and Yunis E. Epstein-Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol 22 (1998) 299-309
31. Gandhi M.K., and Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 4 (2004) 725-738
32. Hale G., and Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 91 (1998) 3079-3083
33. Ho M., Jaffe R., Miller G., et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 45 (1988) 719-727
34. Thomas J.A., Crawford D.H., and Burke M. Clinicopathologic implications of Epstein-Barr virus related B cell lymphoma in immunocompromised patients. J Clin Pathol 48 (1995) 287-290
35. Beatty P.R., Krams S.M., Esquivel C.O., and Martinez O.M. Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. Transplantation 65 (1998) 1248-1255
36. Majewski M., Korecka M., Kossev P., et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A 97 (2000) 4285-4290
37. Haque T., and Crawford D.H. Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders. Springer Semin Immunopathol 20 (1998) 375-387
38. Gratama J.W., Oosterveer M.A., Zwaan F.E., Lepoutre J., Klein G., and Ernberg I. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci USA 85 (1988) 8693-8696
39. Meijer E., Dekker A.W., Weersink A.J., Rozenberg-Arska M., and Verdonck L.F. Prevention and treatment of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants. Br J Haematol 119 (2002) 596-607
40. Choquet S., Oertel S., LeBlond V., et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 86 (2007) 599-607
41. Ghobrial I.M., Habermann T.M., Maurer M.J., et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 23 (2005) 7574-7582
42. Leblond V., Dhedin N., Mamzer Bruneel M.F., et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 19 (2001) 772-778
43. Tsai D.E., Hardy C.L., Tomaszewski J.E., et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71 (2001) 1076-1088
44. Elstrom R.L., Andreadis C., Aqui N.A., et al. Treatment of PTLD with Rituximab or Chemotherapy. Am J Transplant 6 (2006) 569-576
45. Paya C.V., Fung J.J., Nalesnik M.A., et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 68 (1999) 1517-1525
46. Knowles D.M., Cesarman E., Chadburn A., et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85 (1995) 552-565
47. Perera S.M., Thomas J.A., Burke M., and Crawford D.H. Analysis of the T-cell micro-environment in Epstein-Barr virus-related post-transplantation B lymphoproliferative disease. J Pathol 184 (1998) 177-184
48. Kashanchi F., Araujo J., Doniger J., et al. Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53. Oncogene 14 (1997) 359-367
49. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant. 2002;17(Suppl 4):31-33, 35-36.
50. Herzig K.A., Juffs H.G., Norris D., et al. A single-centre experience of post-renal transplant lymphoproliferative disorder. Transpl Int 16 (2003) 529-536
51. Milpied N., Vasseur B., Parquet N., et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 11 Suppl 1 (2000) 113-116
52. González-Barca E., Domingo-Domenech E., Javier Capote F., et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 92 (2007) 1489-1494
53. Trappe R., Choquet S., Oertel S., et al. Sequential Treatment with Rituximab and CHOP chemotherapy in B-cell PTLD - A new standard in Therapy?. Blood 110 (2007) 390 Abstract
54. Nehring A.K., Dua U., Mollee P., et al. Epstein-Barr virus T-cell immunity despite rituximab. Br J Haematol (2007)
55. Savoldo B., Rooney C.M., Quiros-Tejeira R.E., et al. Cellular immunity to epstein-barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 5 (2005) 566-572
56. Starzl T.E., Nalesnik M.A., Porter K.A., et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1 (1984) 583-587
57. Hanto D.W., Frizzera G., Gajl-Peczalska K.J., and Simmons R.L. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 39 (1985) 461-472
58. Mentzer S.J., Fingeroth J., Reilly J.J., Perrine S.P., and Faller D.V. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Cells Mol Dis 24 (1998) 114-123
59. Perrine S.P., Hermine O., Small T., et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 109 (2007) 2571-2578
60. Feng W.H., Hong G., Delecluse H.J., and Kenney S.C. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 78 (2004) 1893-1902
61. Rooney C.M., Smith C.A., Ng C.Y., et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92 (1998) 1549-1555
62. Comoli P., Labirio M., Basso S., et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99 (2002) 2592-2598
63. Comoli P., Maccario R., Locatelli F., et al. Treatment of EBV-Related Post-Renal Transplant Lymphoproliferative Disease with a Tailored Regimen Including EBV-Specific T Cells. Am J Transplant 5 (2005) 1415-1422
64. Wilkie G.M., Taylor C., Jones M.M., et al. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases. J Immunother 27 (2004) 309-316
65. Haque T., Wilkie G.M., Taylor C., et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360 (2002) 436-442
66. Wynn R.F., Arkwright P.D., Haque T., et al. Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation. Lancet Oncol 6 (2005) 344-346
67. Haque T., Wilkie G.M., Jones M.M., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110 (2007) 1123-1131
68. Gandhi M.K., Wilkie G.M., Dua U., et al. Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am J Transplant 7 (2007) 1293-1299
69. Savoie A., Perpete C., Carpentier L., Joncas J., and Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 83 (1994) 2715-2722
70. Wagner H.J., Wessel M., Jabs W., et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 72 (2001) 1012-1019
71. Yang J., Tao Q., Flinn I.W., et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 96 (2000) 4055-4063
72. Harris N.L., and Swerdlow S.H. Methotrexate-associated lymphoproliferative disorders. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (2001), International Agency for Research on Cancer Press, Lyon 270-271
73. Tran H, Cheung C, Gill D, et al. Methotrexate-associated mantle-cell lymphoma in an elderly man with myasthenia gravis. Nat Clin Pract Oncol (in press).
74. Georgescu L., and Paget S.A. Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate?. Drug Saf 20 (1999) 475-487
75. Moder K.G., Tefferi A., Cohen M.D., Menke D.M., and Luthra H.S. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 99 (1995) 276-281
76. Kremer J.M. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years. Arthritis Rheum 40 (1997) 984-985
77. Weinblatt M.E., Maier A.L., Fraser P.A., and Coblyn J.S. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 25 (1998) 238-242
78. Cockburn I.T., and Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun 2 (1989) 723-731
79. Mariette X., Cazals-Hatem D., Warszawki J., Liote F., Balandraud N., and Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99 (2002) 3909-3915
80. Hakulinen T., Isomaki H., and Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 78 (1985) 29-32
81. Franklin J., Lunt M., Bunn D., Symmons D., and Silman A. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 65 (2006) 617-622
82. Johnston A., Gudjonsson J.E., Sigmundsdottir H., Ludviksson B.R., and Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 114 (2005) 154-163
83. Matsuo K., Suzuki R., Hamajima N., et al. Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood 97 (2001) 3205-3209
84. Niclot S., Pruvot Q., Besson C., et al. Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas. Blood 108 (2006) 278-285
85. Lincz L.F., Scorgie F.E., Kerridge I., Potts R., Spencer A., and Enno A. Methionine synthase genetic polymorphism MS A2756G alters susceptibility to follicular but not diffuse large B-cell non-Hodgkin's lymphoma or multiple myeloma. Br J Haematol 120 (2003) 1051-1054
86. Hishida A., Matsuo K., Hamajima N., et al. Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma. Haematologica 88 (2003) 159-166
87. Skibola C.F., Forrest M.S., Coppede F., et al. Polymorphisms and haplotypes in folate-metabolizing genes and risk of non-Hodgkin lymphoma. Blood 104 (2004) 2155-2162
88. Lim U., Wang S.S., Hartge P., et al. Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER case-control study. Blood 109 (2007) 3050-3059
89. Salloum E., Cooper D.L., Howe G., et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 14 (1996) 1943-1949
90. Kamel O.W., van de Rijn M., Weiss L.M., et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 328 (1993) 1317-1321
91. Kamel O.W., Weiss L.M., van de Rijn M., Colby T.V., Kingma D.W., and Jaffe E.S. Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol 20 (1996) 1279-1287
92. Tosato G., Steinberg A.D., Yarchoan R., et al. Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J Clin Invest 73 (1984) 1789-1795
93. Feng W.H., Cohen J.I., Fischer S., et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst 96 (2004) 1691-1702
94. Tosato G., Steinberg A.D., and Blaese R.M. Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med 305 (1981) 1238-1243
95. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Jama 295 (2006) 2275-2285
96. Geborek P., Bladstrom A., Turesson C., et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64 (2005) 699-703
97. Hansen R.A., Gartlehner G., Powell G.E., and Sandler R.S. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol 5 (2007) 729-735
98. Askling J., Fored C.M., Baecklund E., et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64 (2005) 1414-1420
99. Wolfe F., and Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56 (2007) 1433-1439
100. Connell W.R., Kamm M.A., Dickson M., Balkwill A.M., Ritchie J.K., and Lennard-Jones J.E. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343 (1994) 1249-1252
101. Farrell R.J., Ang Y., Kileen P., et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 47 (2000) 514-519
102. Bucher C., Degen L., Dirnhofer S., et al. Biologics in inflammatory disease: infliximab associated risk of lymphoma development. Gut 54 (2007) 732-733
103. Rosh J.R., Gross T., Mamula P., Griffiths A., and Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?. Inflamm Bowel Dis 13 (2007) 1024-1030
104. Sanli H., Ataman S., Akay B.N., Yilmaz A., Yildizlar D., and Gurgey E. Mycosis fungoides in a patient with ankylosing spondylitis during infliximab therapy. J Drugs Dermatol 6 (2007) 834-836
105. Zeidan A., Sham R., Shapiro J., Baratta A., and Kouides P. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy. Leuk Lymphoma 48 (2007) 1410-1413
106. Erickson S.L., de Sauvage F.J., Kikly K., et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372 (1994) 560-563
107. Feldmann M., Elliott M.J., Woody J.N., and Maini R.N. Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol 64 (1997) 283-350
108. Bonnet F., Balestre E., Thiebaut R., et al. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France. Clin Infect Dis 42 (2006) 411-417
109. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92:1823-30.
110. Grulich A.E., Wan X., Law M.G., et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. Aids 14 (2000) 133-140
111. Delecluse H.J., Hummel M., Marafioti T., Anagnostopoulos I., and Stein H. Common and HIV-related diffuse large B-cell lymphomas differ in their immunoglobulin gene mutation pattern. J Pathol 188 (1999) 133-138
112. Shiramizu B., Herndier B.G., and McGrath M.S. Identification of a common clonal human immunodeficiency virus integration site in human immunodeficiency virus-associated lymphomas. Cancer Res 54 (1994) 2069-2072
113. Dean M., Jacobson L.P., McFarlane G., et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res 59 (1999) 3561-3564
114. D'Apuzzo M., Rolink A., Loetscher M., et al. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol 27 (1997) 1788-1793
115. Mounier N., Spina M., and Gisselbrecht C. Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol 136 (2007) 685-698
116. Sparano J.A. HIV-associated lymphoma: the evidence for treating aggressively but with caution. Curr Opin Oncol 19 (2007) 458-463
117. Tulpule A., Sherrod A., Dharmapala D., et al. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res 26 (2002) 121-127
118. Sparano J.A., Wiernik P.H., Hu X., Sarta C., Henry D.H., and Ratech H. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. Med Oncol 15 (1998) 50-57
119. Bower M., Stebbing J., Tuthill M., et al. Immunological recovery in survivors following chemotherapy for AIDS related non Hodgkin's lymphoma. Blood (2008)
120. Sarker D., Thirlwell C., Nelson M., Gazzard B., and Bower M. Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma. Aids 17 (2003) 861-865
121. Kaplan L.D., Lee J.Y., Ambinder R.F., et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 106 (2005) 1538-1543
122. Spina M., Jaeger U., Sparano J.A., et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 105 (2005) 1891-1897
123. Gabarre J., Azar N., Autran B., Katlama C., and Leblond V. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet 355 (2000) 1071-1072
124. Gabarre J., Marcelin A.G., Azar N., et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica 89 (2004) 1100-1108
125. Carbone A., Gloghini A., and Gaidano G. KSHV/HHV8 Doesn't Play a Significant Role in the Development of Plasmablastic Lymphoma of the Oral Cavity. Am J Surg Pathol 32 (2008) 172-174
126. Flinn I.W., and Ambinder R.F. AIDS primary central nervous system lymphoma. Curr Opin Oncol 8 (1996) 373-376
127. Besson C., Goubar A., Gabarre J., et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 98 (2001) 2339-2344
128. Raez L.E., Patel P., Feun L., Restrepo A., Raub Jr. W.A., and Cassileth P.A. Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL). Crit Rev Oncog 9 (1998) 199-208
129. Maher E.A., and Fine H.A. Primary CNS lymphoma. Semin Oncol 26 (1999) 346-356
130. Johnson B.A., Fram E.K., Johnson P.C., and Jacobowitz R. The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. AJNR Am J Neuroradiol 18 (1997) 563-572
131. Skolasky R.L., Dal Pan G.J., Olivi A., Lenz F.A., Abrams R.A., and McArthur J.C. HIV-associated primary CNS lymorbidity and utility of brain biopsy. J Neurol Sci 163 (1999) 32-38
132. Antinori A., De Rossi G., Ammassari A., et al. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol 17 (1999) 554-560
133. Castagna A., Cinque P., d'Amico A., Messa C., Fazio F., and Lazzarin A. Evaluation of contrast-enhancing brain lesions in AIDS patients by means of Epstein-Barr virus detection in cerebrospinal fluid and 201thallium single photon emission tomography. Aids 11 (1997) 1522-1523
134. Jacomet C., Girard P.M., Lebrette M.G., Farese V.L., Monfort L., and Rozenbaum W. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. Aids 11 (1997) 1725-1730
135. Newell M.E., Hoy J.F., Cooper S.G., et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer 100 (2004) 2627-2636
136. Hoffmann C., Tabrizian S., Wolf E., et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. Aids 15 (2001) 2119-2127
137. Pajonk F., and McBride W.H. Survival of AIDS patients with primary central nervous system lymphoma may be improved by the radiosensitizing effects of highly active antiretroviral therapy. Aids 16 (2002) 1195-1196
138. Goedert J.J., Cote T.R., Virgo P., et al. Spectrum of AIDS-associated malignant disorders. Lancet. 351 (1998) 1833-1839
139. Biggar R.J., Jaffe E.S., Goedert J.J., Chaturvedi A., Pfeiffer R., and Engels E.A. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108 (2006) 3786-3791
140. Herida M., Mary-Krause M., Kaphan R., et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 21 (2003) 3447-3453
141. Palella Jr. F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 338 (1998) 853-860
142. Gerard L., Galicier L., Boulanger E., et al. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. Aids 17 (2003) 81-87
143. Glaser S.L., Clarke C.A., Gulley M.L., et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998. Cancer 98 (2003) 300-309
144. Hartmann P., Rehwald U., Salzberger B., et al. BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol 14 (2003) 1562-1569
145. Spina M., Gabarre J., Rossi G., et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 100 (2002) 1984-1988
146. Jenner R.G., Maillard K., Cattini N., et al. Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci U S A 100 (2003) 10399-10404
147. Fais F., Gaidano G., Capello D., et al. Immunoglobulin V region gene use and structure suggest antigen selection in AIDS-related primary effusion lymphomas. Leukemia 13 (1999) 1093-1099
148. Arguello M., Sgarbanti M., Hernandez E., et al. Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines. Oncogene 22 (2003) 964-973
149. Carbone A., and Gloghini A. KSHV/HHV8-associated lymphomas. Br J Haematol 140 (2008) 13-24
150. Parravicini C., Chandran B., Corbellino M., et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 156 (2000) 743-749
151. Cesarman E., Chang Y., Moore P.S., Said J.W., and Knowles D.M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332 (1995) 1186-1191
152. Fujimuro M., Wu F.Y., ApRhys C., et al. A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat Med 9 (2003) 300-306
153. Aoki Y., and Tosato G. Targeted inhibition of angiogenic factors in AIDS-related disorders. Curr Drug Targets Infect Disord 3 (2003) 115-128
154. Sin S.H., Roy D., Wang L., et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 109 (2007) 2165-2173
155. Aoki Y., Feldman G.M., and Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101 (2003) 1535-1542
156. Prakash O., Swamy O.R., Peng X., et al. Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis. Blood 105 (2005) 3987-3994
157. Simonelli C., Spina M., Cinelli R., et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 21 (2003) 3948-3954
158. Boulanger E., Daniel M.T., Agbalika F., and Oksenhendler E. Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma. Am J Hematol 73 (2003) 143-148
159. Ghosh S.K., Wood C., Boise L.H., et al. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. Blood 101 (2003) 2321-2327
160. Wang S.S., Slager S.L., Brennan P., et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 109 (2007) 3479-3488
161. Diepstra A., Niens M., Vellenga E., et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet 365 (2005) 2216-2224
162. Hjalgrim H., Askling J., Rostgaard K., et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 349 (2003) 1324-1332
163. Guzowski D., Chandrasekaran A., Gawel C., et al. Analysis of single nucleotide polymorphisms in the promoter region of interleukin-10 by denaturing high-performance liquid chromatography. J Biomol Tech 16 (2005) 154-166
164. Rothman N., Skibola C.F., Wang S.S., et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7 (2006) 27-38
165. Nieters A., Beckmann L., Deeg E., and Becker N. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 7 (2006) 615-624
166. Wang S.S., Cozen W., Cerhan J.R., et al. Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res 67 (2007) 5042-5054
167. Warzocha K., Ribeiro P., Bienvenu J., et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 91 (1998) 3574-3581
168. Lech-Maranda E., Baseggio L., Bienvenu J., et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 103 (2004) 3529-3534
169. Hill D.A., Wang S.S., Cerhan J.R., et al. Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. Blood 108 (2006) 3161-3167
170. Gemmati D., Ongaro A., Scapoli G.L., et al. Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults. Cancer Epidemiol Biomarkers Prev 13 (2004) 787-794
171. Hishida A., Matsuo K., Hamajima N., et al. Polymorphism in the hMSH2 gene (gIVS 12-6T->C) and risk of non-Hodgkin lymphoma in a Japanese population. Cancer Genet Cytogenet 147 (2003) 71-74
172. Shen M., Zheng T., Lan Q., et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Hum Genet 119 (2006) 659-668
173. van Besien K., Ha C.S., Murphy S., et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91 (1998) 1178-1184
174. Kuze T., Nakamura N., Hashimoto Y., Sasaki Y., and Abe M. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(+) and EBV(-) cases in Japanese population. Jpn J Cancer Res 91 (2000) 1233-1240
175. Park S., Lee J., Ko Y.H., et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 110 (2007) 972-978